Intra-bronchial obstructing device that controls biological interaction with the patient

1 . A method of treating a lung of a patient using an intra-bronchial device while controlling biological interaction of the device with the patient, the method including the steps of: providing an intra-bronchial device that comprises a one-way valve, the intra-bronchial device precludes air from being inhaled through an air passageway into a lung portion when inserted into the air passageway communicating with the portion of the lung; associating a medicant that controls the biological interaction with the intra-bronchial device; and inserting the intra-bronchial device in the air passageway.

2 . The method of claim 1 , wherein the step of associating the medicant with the intra-bronchial device is performed before the step of inserting the device.

3 . The method of claim 1 , wherein the step of associating the medicant with the intra-bronchial device includes overlying at least a portion of the intra-bronchial device with the medicant.

4 . The method of claim 1 , wherein the step of associating the medicant with the intra-bronchial device includes impregnating at least a portion of the intra-bronchial device with the medicant.

5 . The method of claim 1 , wherein the intra-bronchial device includes an absorptive member, and wherein the step of associating the medicant with the intra-bronchial device includes absorption of the medicant by the absorptive member.

6 . The method of claim 1 , wherein the medicant is selected from a group consisting of tissue growth inhibitors, tissue growth enhancers, anti-microbial agents, anti-inflammatory agents, and biological reaction inhibitors.

7 . The method of claim 1 , wherein the medicant is arranged to control biological interaction over a period of time.

8 . A method of claim 1 , including the further steps of providing a cavity in the intra-bronchial device for receiving the medicant; and associating the medicant with the cavity.

9 . The method of claim 8 , wherein the step of associating the medicant with the intra-bronchial device is performed before the step of implanting the device.

10 . The method of claim 8 , wherein the cavity includes an absorptive member, and wherein the step of associating medicant with the intra-bronchial device includes absorption of the medicant by the absorptive member.

11 . The method of claim 8 , wherein the medicant is selected from a group consisting of tissue growth inhibitors, tissue growth enhancers, anti-microbial agents, anti-inflammatory agents, and biological reaction inhibitors.

12 . The method of claim 8 , wherein the medicant is arranged to control biological interaction over a period of time.

13 . A method of treating a lung comprising:

providing an implantable obstruction device at a distal end of a delivery catheter, the obstruction device comprising a membrane on an outer portion thereof;

associating a medicant with the obstruction device;

guiding the distal end of the catheter to a delivery site in a lung and deploying the obstruction device in an air passageway of the lung so as to preclude air flow in at least one direction through the air passageway; and

removing the catheter from the lung and leaving the implanted obstruction device in place;

wherein the obstruction device comprises a one-way valve and further comprising placing the obstruction device in an air passageway in an orientation that prevents fluid from flowing distal of the device while allowing fluid to travel in a proximal direction past the device.

14 . The method of claim 13 , wherein associating a medicant with the obstruction device comprises coating an exterior portion of the membrane with the medicant.

15 . The method of claim 13 , further comprising injecting a medicant into a lung portion distal of the delivery site prior to deploying the obstruction device.

16 . A method of treating a lung comprising:

providing an implantable obstruction device at a distal end of a delivery catheter, the obstruction device comprising a membrane on an outer portion thereof;

associating a medicant with the obstruction device;

guiding the distal end of the catheter to a delivery site in a lung and deploying the obstruction device in an air passageway of the lung so as to preclude air flow in at least one direction through the air passageway;

removing the catheter from the lung and leaving the implanted obstruction device in place; and

configuring and deploying the obstruction device so as to maintain a mucociliary pathway between a distal side and a proximal side of the obstruction device.

17 . The method of claim 13 , wherein associating a medicant with the obstruction device comprises placing the medicant in a hollow cavity in the obstruction device.

18 . The method of claim 13 , wherein associating a medicant with the obstruction device comprises absorbing the medicant into an absorbent member carried by the obstruction device.

19 . The method of claim 13 , wherein the medicant is at least one member of the group consisting of tissue growth inhibitors, tissue growth enhancers, anti-microbial agents, anti-inflammatory agents, and biological reaction inhibitors.

20 . The method of claim 1 , further comprising placing the intra-bronchial device in an air passageway in an orientation that substantially prevents fluid from flowing in a distal direction past the intra-bronchial device while allowing fluid to travel in a proximal direction past the intra-bronchial device.

21 . The method of claim 1 , further comprising configuring and deploying the intra-bronchial device so as to maintain a mucociliary pathway for mucus transport past the intra-bronchial device.